Do Hung Form 4 January 17, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(Print or Type Responses)

1. Name and Address of Reporting Person * Do Hung

2. Issuer Name and Ticker or Trading Symbol

AMICUS THERAPEUTICS, INC. [FOLD]

(Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

01/15/2019

C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE

(First)

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

5. Relationship of Reporting Person(s) to

(Check all applicable)

Chief Science Officer

10% Owner

_ Other (specify

OMB APPROVAL

3235-0287

January 31,

2005

0.5

OMB

Number:

Expires:

response...

Estimated average

burden hours per

Applicable Line)

Director

_X__ Officer (give title

Issuer

below)

X Form filed by One Reporting Person Form filed by More than One Reporting

CRANBURY, NJ 08512

(City)	(State)	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed 3. 4. Se Execution Date, if Transaction(A) of				` ′	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
G.			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	01/15/2019		M	4,400	A	\$ 2.94	452,713	D		
Common Stock	01/15/2019		M	3,800	A	\$ 5.13	456,513	D		
Common Stock	01/15/2019		S(1)	16,600	D	\$ 12	439,913	D		
Common Stock	01/16/2019		M	4,988	A	\$ 2.94	444,901	D		
Common Stock	01/16/2019		M	30,036	A	\$ 5.13	474,937	D		

Edgar Filing: Do Hung - Form 4

Common $S_{\underline{}}^{(1)}$ 01/16/2019 36,669 D 12.05 438,268 D Stock (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	TransactionDerivative Code Securities		6. Date Exerc Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	\$ 2.94	01/15/2019		M		4,400	<u>(3)</u>	06/26/2024	Common Stock	4,400
Stock Options (right to buy)	\$ 5.13	01/15/2019		M		3,800	<u>(4)</u>	01/03/2027	Common Stock	3,800
Stock Options (right to buy)	\$ 2.94	01/16/2019		M		4,988	(3)	06/26/2024	Common Stock	4,988
Stock Options (right to buy)	\$ 5.13	01/16/2019		M		30,036	<u>(4)</u>	01/03/2027	Common Stock	30,036

Reporting Owners

Relationships Reporting Owner Name / Address

> Director 10% Owner Officer Other

Chief Science Officer Do Hung

C/O AMICUS THERAPEUTICS, INC.

2 Reporting Owners

Edgar Filing: Do Hung - Form 4

1 CEDAR BROOK DRIVE CRANBURY, NJ 08512

Signatures

/s/Christian Formica, Attorney-In-Fact

01/17/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale of common stock was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2018.
- This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$12.00 to \$12.23. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- (3) All of the options were fully vested and exercisable as of January 15, 2019.
- These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate (4) number of options granted, vests on January 3, 2018. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2018, with the final installment vesting on January 1, 2021.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3